RxSight Q3 revenue down 14% YoY to $30.3M; net loss widens to $9.8M

RxSight, Inc.

2025-Q3 EPS reported -$0.73 revenue$101,871,000

Revenue $30.3M (-14% YoY); LAL volume up 6% but LDD placements down 68%.
Net loss $(9.8)M ($(0.24)/share) vs $(6.3)M ($(0.16)/share) in Q3 2024.
Adjusted net loss $(1.7)M ($(0.04)/share) vs adjusted net gain $0.2M prior year.
Narrowed FY2025 revenue guidance to $125-130M (prior $120-130M); raised gross margin guidance to 76-77%.
Cash and investments $227.5M, unchanged from June 30, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.